ReviewDiseases (Basel, Switzerland)2026
Early Detection of Gastric Cancer: Linking Epidemiology, Pathophysiology, and Innovations in Digestive Endoscopy.
Review in Diseases (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
objectivesDespite substantial progress in understanding its pathophysiology and risk factors, gastric cancer remains a significant global health burden. Advances in endoscopic technology have improved the potential for early detection, yet variability in clinical practice persists. In this comprehensive narrative review, we summarize the most recent epidemiological trends in gastric pre-neoplastic and neoplastic lesions and critically appraise current evidence on optimizing endoscopic techniques and strategies for the detection of early gastric neoplasia, with an emphasis on emerging innovations.
methodsThe relevant literature on epidemiology, risk factors, pathophysiology, and endoscopic management of GC was selectively reviewed based on the authors' expertise and appraisal of contemporary evidence.
resultsMarked global disparities persist in GC incidence, mortality, and stage at diagnosis. Interval GC-including missed lesions and so-called "true" interval cancers-remains a clinically relevant challenge and is frequently identified at advanced stages. These gaps are partly attributable to inconsistent quality in diagnostic esophagogastroduodenoscopy (EGD). High-quality EGD relies on adequate mucosal inspection time, systematic photodocumentation, optimal gastric preparation, and the use of standardized terminology, including mucosal visibility scores. Routine integration of chromoendoscopy and magnification techniques further enhances detection rates. Looking ahead, artificial intelligence holds promise as a transformative adjunct to standardize and augment real-time lesion recognition and quality assurance.
conclusionsHigh-quality endoscopic evaluation, coupled with tailored surveillance strategies, enables earlier detection of pre-neoplastic lesions and early gastric cancer, improving clinical outcomes. Future priorities include broadening access to high-quality endoscopy, harmonizing performance standards, and promoting continuous training alongside technological integration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.